LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Pipeline I-Mab's focus on precision immuno-oncology agents, especially the bispecific antibody givastomig targeting Claudin 18.2 and 4-1BB, highlights a promising product pipeline with potential for strategic partnerships or licensing deals in the oncology sector.

Recent Funding Boost The company secured a strategic equity investment of $30.9 million from Everest Medicines, indicating strong investor confidence and potential financial support for expanding clinical development and commercialization efforts.

Active Industry Presence Participation in major conferences such as AACR, ESMO GI, and healthcare life sciences events presents opportunities for partnering with key opinion leaders and stakeholders to promote innovative immuno-oncology therapies.

Leadership Transition Recent changes in executive leadership, including the appointment of a new CEO, signal a strategic shift that could open avenues for collaboration with new leadership teams interested in innovative biotech assets.

Growth Potential With a revenue range of $25M to $50M and a relatively small team, I-Mab offers potential for early-stage collaborations, licensing agreements, or distribution partnerships targeting expanding markets in immuno-oncology therapeutics.

I-Mab Biopharma Tech Stack

I-Mab Biopharma uses 8 technology products and services including Baidu Analytics, Drupal, WordPress, and more. Explore I-Mab Biopharma's tech stack below.

  • Baidu Analytics
    Analytics
  • Drupal
    Content Management System
  • WordPress
    Content Management System
  • Microsoft Word
    Office Suites
  • Planisware
    Project Management
  • Akamai Bot Manager
    Security
  • Bootstrap
    UI Frameworks
  • GoDaddy
    Web Hosting

Media & News

I-Mab Biopharma's Email Address Formats

I-Mab Biopharma uses at least 1 format(s):
I-Mab Biopharma Email FormatsExamplePercentage
First.Last@i-mabbiopharma.comJohn.Doe@i-mabbiopharma.com
49%
LF@i-mabbiopharma.comDJ@i-mabbiopharma.com
1%
First@i-mabbiopharma.comJohn@i-mabbiopharma.com
1%
First.Last@i-mabbiopharma.comJohn.Doe@i-mabbiopharma.com
49%

Frequently Asked Questions

Where is I-Mab Biopharma's headquarters located?

Minus sign iconPlus sign iconI-Mab Biopharma's main headquarters is located at 2440 Research Boulevard, Suite 400. The company has employees across 3 continents, including AsiaNorth AmericaEurope.

What is I-Mab Biopharma's phone number?

Minus sign iconPlus sign icon You can contact I-Mab Biopharma's main corporate office by phone at
+1-301-670-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is I-Mab Biopharma's official website and social media links?

Minus sign iconPlus sign iconI-Mab Biopharma's official website is i-mabbiopharma.com and has social profiles on LinkedInCrunchbase.

What is I-Mab Biopharma's SIC code NAICS code?

Minus sign iconPlus sign iconI-Mab Biopharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does I-Mab Biopharma have currently?

Minus sign iconPlus sign iconAs of December 2025, I-Mab Biopharma has approximately 120 employees across 3 continents, including AsiaNorth AmericaEurope. Key team members include Ceo & Board Member: X. S. F.Chief Executive Officer: R. K.Chief Executive Officer: R. K.. Explore I-Mab Biopharma's employee directory with LeadIQ.

What industry does I-Mab Biopharma belong to?

Minus sign iconPlus sign iconI-Mab Biopharma operates in the Biotechnology Research industry.

What technology does I-Mab Biopharma use?

Minus sign iconPlus sign iconI-Mab Biopharma's tech stack includes Baidu AnalyticsDrupalWordPressMicrosoft WordPlaniswareAkamai Bot ManagerBootstrapGoDaddy.

What is I-Mab Biopharma's email format?

Minus sign iconPlus sign iconI-Mab Biopharma's email format typically follows the pattern of First.Last@i-mabbiopharma.com. Find more I-Mab Biopharma email formats with LeadIQ.

How much funding has I-Mab Biopharma raised to date?

Minus sign iconPlus sign icon As of December 2025, I-Mab Biopharma has raised $65M in funding. The last funding round occurred on Aug 01, 2025 for $65M.

When was I-Mab Biopharma founded?

Minus sign iconPlus sign iconI-Mab Biopharma was founded in 2016.

I-Mab Biopharma

Biotechnology ResearchMaryland, United States51-200 Employees

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.

Section iconCompany Overview

Headquarters
2440 Research Boulevard, Suite 400
Phone number
+1-301-670-****
Website
i-mabbiopharma.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $65M

    I-Mab Biopharma has raised a total of $65M of funding over 5 rounds. Their latest funding round was raised on Aug 01, 2025 in the amount of $65M.

  • $25M$50M

    I-Mab Biopharma's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $65M

    I-Mab Biopharma has raised a total of $65M of funding over 5 rounds. Their latest funding round was raised on Aug 01, 2025 in the amount of $65M.

  • $25M$50M

    I-Mab Biopharma's revenue is estimated to be in the range of $25M$50M

Company Leadership

  • Stylized image of a person
    X. S. F.
    Ceo & Board Member
    Phone icon
    Mobile Phone
  • Stylized image of a person
    R. K.
    Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    R. K.
    Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. X.
    Cco Executive Assistant
    Phone icon
    Mobile Phone
  • Stylized image of a person
    P. D.
    Chief Medical Officer
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    R. K.
    Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    R. K.
    Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. Q.
    Evp And Head Of Cmc
    Phone icon
    Mobile Phone
  • Stylized image of a person
    C. X.
    Vice President Clinical Development
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. S.
    Head Of Audit, Risks And Compliance
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.